Medication info

Terbinafine Tablets (Terbinafine Hydrochloride)

Prescription medicationTabletExpired
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Ankuk Pharmaceutical Co., Ltd.
Appearance
White round tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Expired

MFDS item code 201903419 · Approved 2019.05.27

This product's status changed to Expired on 2024.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of onychomycosis, cutaneous fungal infections (e.g., tinea pedis and tinea corporis), and tinea capitis
Who uses it
Adults · Children
Adult dosage
Administer 125 mg of terbinafine twice daily or 250 mg once daily. The duration of treatment according to the disease is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. The treatment period may be shortened to 3 months or less in patients with infection of a fingernail or a relatively small toenail, or in younger patients. A 3-month treatment period is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow toenail growth. Reduce the daily dose by 1/2 in patients with creatinine clearance below 50 mL per minute.
Children's dosage
Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be administered regularly for the prescribed duration. Body weight under 20 kg (under 5 years): Administer 62.5 mg once daily. Because experience with administration is limited, the decision to treat should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Ingredients

Manufacturer
Ankuk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of onychomycosis, cutaneous fungal infections (e.g., tinea pedis and tinea corporis), and tinea capitis

  • Dermatophyte infections
  • athlete's foot
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used to treat dermatophyte infections such as athlete's foot, tinea corporis, and tinea cruris caused by dermatophytes in adults. It is also effective against fungal infections affecting the nails. Additionally, it is used in children for the treatment of tinea capitis. Therefore, it is primarily used to improve fungal infections of the skin and nails.

Dosage and Administration

Adult dosage

Administer 125 mg of terbinafine twice daily or 250 mg once daily. The duration of treatment according to the disease is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. The treatment period may be shortened to 3 months or less in patients with infection of a fingernail or a relatively small toenail, or in younger patients. A 3-month treatment period is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients with slow toenail growth. Reduce the daily dose by 1/2 in patients with creatinine clearance below 50 mL per minute.

Children's dosage

Administer to children aged 2 years and older. Use is not recommended in children under 2 years of age because there is no experience with administration in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be administered regularly for the prescribed duration. Body weight under 20 kg (under 5 years): Administer 62.5 mg once daily. Because experience with administration is limited, the decision to treat should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Precautions

This medication is not recommended for patients with chronic liver disease or active liver disease. Before administration, liver disease status must be confirmed, and liver function tests should be carried out regularly. If symptoms of liver dysfunction are suspected, such as persistent nausea, loss of appetite, fatigue, vomiting, right upper abdominal pain, or jaundice, consult a physician immediately. This medication can cause severe liver damage leading to hepatic failure; therefore, administration should be discontinued if liver dysfunction is confirmed. This medication should not be administered to those with allergies to this drug or its components, patients with blood disorders, severe renal failure, infants under 2 years of age, nursing mothers, or patients with specific genetic digestive disorders. Caution is required when administering this medication to patients with decreased renal function, the elderly, children under 20 kg, or patients with psoriasis or systemic lupus erythematosus. Additionally, close observation of skin conditions is essential due to the potential for serious skin reactions. Adverse reactions may occur in various systems including the liver, blood, skin, musculoskeletal system, gastrointestinal, and nervous systems, so symptoms should be reported to healthcare professionals promptly. Common symptoms include myalgia, fatigue, rash, headache, taste disturbances, depression, etc. This medication should only be used for the treatment of fungal infections, and caution is advised when driving or operating machinery if dizziness occurs. Interactions may occur when used in conjunction with other medications; therefore, healthcare professionals should be informed of any ongoing medications as dosage adjustments may be necessary. Women who are pregnant or may become pregnant should carefully consider the benefits and risks when using this medication, and nursing mothers should discontinue breastfeeding if using this drug. Overdose may result in headache, nausea, upper abdominal pain, and dizziness, requiring immediate medical attention. This medication should be kept out of reach of children, protected from direct sunlight, and stored at room temperature.

Side effects

Persistent nausea, loss of appetite, fatigue, vomiting, right upper quadrant pain, jaundice, dark urine, loose stools, cholangiohepatic failure, hepatitis, bile duct obstruction, jaundice, rash, skin itching, fever, nausea, vomiting, anorexia, lethargy, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, desquamative dermatitis, blistering dermatitis, psoriatic rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, elevated serum myoglobin, elevated urinary myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial swelling, lymphangiectasia, abdominal distension, dyspepsia, mild abdominal pain, diarrhea, gastric discomfort, thirst, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, sensory disturbance, sensory decrease, decreased attention, insomnia, elevated BUN, pollakiuria, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol, elevated triglycerides, lethargy, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, diminished vision, hearing loss, auditory impairment, vasculitis, permanent loss of smell, anosmia, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, elevated serum creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or humidity; therefore, it must be stored in a tightly closed container. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White round tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.